{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-24-000074","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2024-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.784217+00:00","generated_at":"2026-06-01T06:18:37.594125+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Autolus publishes UK Annual Report; provides obe-cel BLA status, PDUFA date Nov 16, 2024","bullets":["BLA for obe-cel accepted by FDA; PDUFA target action date set for 16 November 2024.","Phase 2 FELIX study data: 78% CR/CRi rate in evaluable r/r adult B-ALL patients; median follow-up 16.6 months.","First two patients enrolled in CARLYSLE Phase 1 trial of obe-cel for SLE; initial data expected by end of 2024.","In Phase 1 ALLCAR19 trial, 41% of patients in ongoing remission at 3-year median follow-up without transplant.","AUTO1/22 dual-targeting CAR T showed 83% MRD-negative complete remission in paediatric r/r B-ALL."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-24-000074","json":"https://secwatch.observer/filing/0001730463-24-000074.json","markdown":"https://secwatch.observer/filing/0001730463-24-000074.md","text":"https://secwatch.observer/filing/0001730463-24-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000074/0001730463-24-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000074/autl-20240605.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:18:37.594125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}